This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Annexin A1 (ANXA1)	Studies in mice identified an ANXA1-targeted peptide that could help treat cancer. In mice with tumors, injection of a phage library led to the identification of tumor-enriched ANXA1-binding peptides. In mouse models of cancer, injection of a lead peptide conjugated to 17-AAG lowered tumor growth compared with vehicle control injection. Next steps include conjugating the peptide to other therapeutics and seeking a corporate partner to sponsor clinical trials. Tanespimycin (17-(allylamino)-17-demethoxygeldanamycin (17-AAG)), a heat shock protein 90 (Hsp90) inhibitor from the Kosan Biosciences Inc. unit of Bristol-Myers Squibb Co., was discontinued last year. SciBX 4(47); doi:10.1038/scibx.2011.1317 Published online Dec. 8, 2011	Patent application filed; available for licensing	Hatakeyama, S. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Nov. 23, 2011; doi:10.1073/pnas.1105057108 Contact: Michiko N. Fukuda, Sanford-Burnham Medical Research Institute, La Jolla, Calif. e-mail: michiko@sanfordburnham.org Contact: Kazuhiro Sugihara, Hamamatsu University School of Medicine, Hamamatsu, Japan e-mail: sugihara@hama-med.ac.jp